Jane Osbourn, Ph.D.Vice President of R&D and Site Leader at MedImmune UK
Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An expert in antibody engineering, Jane has authored many key publications and patents, and made a significant contribution to the discovery and development of a number of marketed drugs and more than 40 clinical candidates. She has worked across many therapy areas and currently leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies. Jane is Site Leader for MedImmune’s facility in Cambridge UK and chairs the cross-campus leadership team for AstraZeneca in Cambridge.
Jane is passionate about the development of the UK biotechnology sector and was elected Chair of the BioIndustry Association (the UK trade association for biotech) in 2015. She is also a Director of Babraham Bioscience Technologies and a Director of Cambridge Enterprise, the technology transfer organization for University of Cambridge.